For Healthcare Professionals Outside the US
Reprinted from Grob JJ, et al. Lancet Oncol. 2015;16(13):1389-1398, Copyright 2015, with permission from Elsevier.
* Denotes statistical significance.
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; PD, progressive disease.
References: 1. Grob J-J, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389-1398. 2. Data on file.